This webinar caught health professionals up on the latest in drug development and clinical trials in pulmonary fibrosis.
It is so heartening to be able to speak optimistically about the future when we see our patients with IPF and other interstitial lung disease in the clinic. Not only do we have two approved drugs, but there are multiple potential breakthrough treatments in clinical development right now, many of them in late phase clinical trials.
Chair: Prof Margaret Wilsher
Presenters: Prof Glen Westall is a Consultant Chest Physician, and Head of the Paediatric Lung Transplant Program at the Alfred Hospital, Melbourne. He trained at King’s College, London; the Alfred Hospital, Melbourne and Royal Brompton Hospital, London. Glen oversees the basic scientific research portfolios of the Alfred’s lung transplant and lung fibrosis service. As an academic clinician, he has established a number of translational projects with industry partners that have taken discoveries in basic science to the clinical interface. In particular he has established biorepositories that collect and store both normal lung tissue and fibrotic lungs.
Prof Dan Chambers is a thoracic and transplant physician with special interests in immunology and interstitial lung disease. Dan’s research focuses on the pathogenesis of lung fibrosis, new diagnostic methods and biomarkers, and therapeutic discovery. His research has been supported by > $15 million in competitive grant funding and he has authored more than 100 research papers. He has been a Principal Investigator for numerous clinical trials of all phases in interstitial and other lung diseases including IPF.
Watch on demand.